Evidence map›Paper›PMID 31395500›Full record

ArticleEBioMedicine2019

A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis.

Nerea Méndez-Barbero, Carmen Gutierrez-Muñoz, Julio Madrigal-Matute, Pablo Mínguez, Jesús Egido, Jean-Baptiste Michel, Jose L Martín-Ventura, Vanesa Esteban, Luis M Blanco-Colio

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Annexin A8 deficiency delays atherosclerosis progression.Clinical and translational medicine · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. The TWEAK/Fn14/CD163 axis-implications for metabolic disease.Reviews in endocrine & metabolic disorders · 2022
    Review
  12. Diabetes and restenosis.Cardiovascular diabetology · 2022
    Review
  13. Article
  14. Article
  15. Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.International journal of environmental research and public health · 2021
    Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Nerea Méndez-BarberoVascular Research Lab, CIBERCV, IIS-Fundación Jiménez Díaz, Madrid, Spain.
Carmen Gutierrez-MuñozVascular Research Lab, CIBERCV, IIS-Fundación Jiménez Díaz, Madrid, Spain.
Julio Madrigal-MatuteDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, USA.
Pablo MínguezDepartment of Genetics and Genomics, IIS-Fundación Jiménez Díaz, Madrid, Spain.
Jesús EgidoRenal and Diabetes Research Lab, CIBERDEM, IIS-Fundación Jiménez Díaz, Madrid, Spain.
Jean-Baptiste MichelINSERM U1148, Laboratory for Vascular Translational Science (LVTS), Paris, France.
Jose L Martín-VenturaVascular Research Lab, CIBERCV, IIS-Fundación Jiménez Díaz, Madrid, Spain.
Vanesa EstebanDepartment of Immunology and ARADyAL, IIS-Fundación Jiménez Díaz, Madrid, Spain. Electronic address: vesteban@fjd.es.
Luis M Blanco-ColioVascular Research Lab, CIBERCV, IIS-Fundación Jiménez Díaz, Madrid, Spain. Electronic address: lblanco@fjd.es.
Centro de Investigación en Red en Enfermedades Cardiovasculares · ESHospital Universitario Fundación Jiménez Díaz · ESAlbert Einstein College of Medicine · USCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor necrosis factor-like weak inducer of apoptosis (Tnfsf12; TWEAK) and its receptor Fibroblast growth factor-inducible 14 (Tnfrsf12a; Fn14) participate in the inflammatory response associated with vascular remodeling. However, the functional effect of TWEAK on vascular smooth muscle cells (VSMCs) is not completely elucidated.

methodsNext generation sequencing-based methods were performed to identify genes and pathways regulated by TWEAK in VSMCs. Flow-citometry, wound-healing scratch experiments and transwell migration assays were used to analyze VSMCs proliferation and migration. Mouse wire injury model was done to evaluate the role of TWEAK/Fn14 during neointimal hyperplasia.

findingsTWEAK up-regulated 1611 and down-regulated 1091 genes in VSMCs. Using a gene-set enrichment method, we found a functional module involved in cell proliferation defined as the minimal network connecting top TWEAK up-regulated genes. In vitro experiments in wild-type or Tnfrsf12a deficient VSMCs demonstrated that TWEAK increased cell proliferation, VSMCs motility and migration. Mechanistically, TWEAK increased cyclins (cyclinD1), cyclin-dependent kinases (CDK4, CDK6) and decreased cyclin-dependent kinase inhibitors (p15

interpretationOur data define a major role of TWEAK/Fn14 in the control of VSMCs proliferation and migration during neointimal hyperplasia after wire injury in mice, and identify TWEAK/Fn14 as a potential target for treating in-stent restenosis. FUND: ISCiii-FEDER, CIBERCV and CIBERDEM.

Indexed as

AngioplastyAnimalsBiomarkersCell MovementCell ProliferationCoronary RestenosisCytokine TWEAKDisease Models, AnimalFlow CytometryGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksImmunohistochemistryMiceMice, KnockoutModels, BiologicalBiomarkersCytokine TWEAKTNFRSF12A protein, humanTNFSF12 protein, humanTWEAK ReceptorCyclinsFn14ProliferationRestenosisTWEAK

Identifiers

PMID31395500
PMCPMC6712059
OpenAlexW2966643586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.